PBYI Q1 2022 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M-53.4% YoY

Gross Profit

$35M76.3% margin

Operating Income

-$747,000-1.6% margin

Net Income

-$3M-7.4% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-17.4%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$201M

Total Liabilities

$194M

Stockholders' Equity

$7M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$98M	-53.4%
Gross Profit	$35M	$69M	-49.1%
Operating Income	-$747,000	$20M	-103.7%
Net Income	-$3M	$17M	-120.6%

Revenue Segments

Product

$41M89%

Royalty

$5M11%